Roche CEO Severin Schwan Fueled By Innovation, Emerging Markets: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Roche CEO Severin Schwan says the Swiss group’s recent revamps, lack of patent expiries, and ongoing drug innovations give the world’s largest maker of cancer drugs a strong position to expand its sales globally, helped by new cutting-edge therapies and creative business approaches.
You may also be interested in...
Ten thousand dollars per month for new oncology drugs has become just about standard, and the trend is not likely to go away soon. Drug makers in 2012 found pricing in oncology to be inelastic and continue to test the boundaries within which payors – and society – will play.
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line+ mBC, but labeling allows first-line treatment in a subset of patients at high risk.
PureTech said it finished 2019 with healthy finances and a promising pipeline which analysts said should offer positive catalysts for the UK group’s stock in 2020.